Quentin S. Blackford Acquires 1,365 Shares of AxoGen, Inc (NASDAQ:AXGN) Stock
AxoGen, Inc (NASDAQ:AXGN) Director Quentin S. Blackford bought 1,365 shares of AxoGen stock in a transaction that occurred on Friday, August 9th. The stock was purchased at an average cost of $13.10 per share, for a total transaction of $17,881.50. Following the acquisition, the director now owns 25,098 shares of the company’s stock, valued at $328,783.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
AXGN stock opened at $14.85 on Thursday. The company has a current ratio of 8.70, a quick ratio of 7.87 and a debt-to-equity ratio of 0.02. AxoGen, Inc has a twelve month low of $11.82 and a twelve month high of $46.25. The business’s 50 day moving average is $18.24. The firm has a market capitalization of $573.52 million, a PE ratio of -27.50 and a beta of 0.18.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. AxoGen had a negative net margin of 26.91% and a negative return on equity of 16.73%. The company had revenue of $26.70 million for the quarter, compared to analysts’ expectations of $26.77 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 29.7% on a year-over-year basis. On average, equities analysts predict that AxoGen, Inc will post -0.72 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in the business. William Blair Investment Management LLC acquired a new position in shares of AxoGen in the 2nd quarter valued at $9,529,000. Frontier Capital Management Co. LLC acquired a new position in shares of AxoGen in the 1st quarter valued at $7,402,000. Baillie Gifford & Co. increased its holdings in shares of AxoGen by 54.0% in the 1st quarter. Baillie Gifford & Co. now owns 980,700 shares of the medical equipment provider’s stock valued at $20,654,000 after acquiring an additional 343,900 shares during the period. D. E. Shaw & Co. Inc. increased its holdings in shares of AxoGen by 89.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 601,118 shares of the medical equipment provider’s stock valued at $11,902,000 after acquiring an additional 284,479 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of AxoGen by 75.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 595,084 shares of the medical equipment provider’s stock valued at $11,783,000 after acquiring an additional 256,697 shares during the period. 87.46% of the stock is currently owned by institutional investors.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Featured Article: How to interpret Moving Average Convergence Divergence (MACD)
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.